The present invention relates to a selective inhibitor of mammalian osteoclast cell activity, processes for its preparation and pharmaceutical compositions comprising the same as well as methods of treatment, where said selective inhibitor is administered to a human or animal patient. Said selective inhibitor has been found to inhibit vacuolar H+-ATPase, such as vacuolar H-ATPase in osteoclast cells, whereby it is therapeutically efficient against physiological disorders involving bone resorption. In an embodiment of the present invention, said selective inhibitor comprises a nicotinonitrile compound with general formula (I).
Salem, Mounir A. I.; Madkour, Hassan M. F.; Soliman, El-Sayed A., Heterocycles, 2000, vol. 53, # 5, p. 1129 - 1143
作者:Salem, Mounir A. I.、Madkour, Hassan M. F.、Soliman, El-Sayed A.、Mahmoud, Naglaa F. H.